within Pharmacolibrary.Drugs.ATC.G;

model G01AF17
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.01,
    Cl             = 0.03 / 1000 / 60,
    adminDuration  = 600,
    adminMass      = 15 / 1000000,
    adminCount     = 1,
    Vd             = 0.001,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.016666666666666666,
    Tlag           = 600
  );

  annotation(Documentation(
    info ="<html><body><p>Oxiconazole is an imidazole-class antifungal agent, primarily used topically to treat skin infections such as athlete's foot, ringworm, and jock itch caused by dermatophytes and yeasts. It is available as a cream and lotion but not typically approved for systemic or oral administration.</p><h4>Pharmacokinetics</h4><p>No published human pharmacokinetic models or parameters for systemic (oral, IV) oxiconazole administration exist. As oxiconazole is almost exclusively used as a topical preparation, systemic absorption is minimal. Parameters below are estimates based on general properties of imidazole antifungals when systemically administered, for a hypothetical adult subject.</p><h4>References</h4><ol><li><p>Kaul, G, et al., &amp; Chopra, S (2023). Oxiconazole Potentiates Gentamicin against Gentamicin-Resistant Staphylococcus aureus . <i>Microbiology spectrum</i> 11(4) e0503122–None. DOI:<a href=&quot;https://doi.org/10.1128/spectrum.05031-22&quot;>10.1128/spectrum.05031-22</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/37428033/&quot;>https://pubmed.ncbi.nlm.nih.gov/37428033</a></p></li><li><p>Mahmoud, RA, et al., &amp; Mansour, HF (2020). Oxiconazole nitrate solid lipid nanoparticles: formulation, in-vitro characterization and clinical assessment of an analogous loaded carbopol gel. <i>Drug development and industrial pharmacy</i> 46(5) 706–716. DOI:<a href=&quot;https://doi.org/10.1080/03639045.2020.1752707&quot;>10.1080/03639045.2020.1752707</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/32266837/&quot;>https://pubmed.ncbi.nlm.nih.gov/32266837</a></p></li><li><p>McClellan, KJ, et al., &amp; Markham, A (1999). Terbinafine. An update of its use in superficial mycoses. <i>Drugs</i> 58(1) 179–202. DOI:<a href=&quot;https://doi.org/10.2165/00003495-199958010-00018&quot;>10.2165/00003495-199958010-00018</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/10439936/&quot;>https://pubmed.ncbi.nlm.nih.gov/10439936</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end G01AF17;
